INTRODUCTION
This paper deals with the risk of importing exotic epidemic disease into the European Union (EU, formerly European Community). The EU consists of fifteen Member States: Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxemburg, The Netherlands, Portugal, Spain, Sweden and the United Kingdom.
At the end of the Second World War, Europe was devastated and a number of countries experienced major epidemics of diseases such as foot and mouth disease (FMD) and hog cholera (classical swine fever). Vigorous eradication programmes have brought most of these epidemic diseases under control. The present situation is that the EU has been historically free from the following diseases:
-vesicular stomatitis -rinderpest -peste des petits ruminants -lumpy skin disease -Rift Valley fever -Teschen disease.
In addition, the EU is only very occasionally invaded by African horse sickness, fowl plague and bluetongue.
The EU is at risk of the importation of disease via the following routes:
-insect vectors (e.g. African horse sickness, bluetongue) -wild birds (e.g. fowl plague, Newcastle disease) -feral animals (e.g. hog cholera) -live domestic animals (e.g. FMD) -animal products (e.g. hog cholera, African swine fever, FMD, swine vesicular disease).
In recent years, two epidemics of FMD have occurred in the EU (Italy and Greece) due to the importation of infected live animals. Hog cholera has recently occurred in EU Member States, partly due to the importation of wild boar meat. Bluetongue also occurred, some time in the past, due to invasion by insect vectors. The introduction of exotic disease is a very real threat to the livestock industry in Europe, and while introduction via wild birds and insect vectors is largely beyond the control of the authorities, the latter can and will exert control over introduction via live animals and animal products.
Animal products include veterinary biologicals, a term which covers a wide range of substances. For the purpose of this discussion, veterinary biologicals will be divided into the following categories:
-crude products, such as fetal calf serum, bovine serum albumin, and other serological products and extracts which have been subjected to minimum treatments -medicinal products, such as vaccines and other immunological products, which have been manufactured and authorised under strict conditions. The risk associated with medicinal products is covered elsewhere in this volume (2, 3) . Production within and importation into the EU is subject to strict legislation.
The 'crude' biological products which pose the greatest threat are fetal calf serum, bovine serum albumin, and other similar serological products and extracts.
The disease agents which are likely to contaminate these crude products are FMD virus, and bluetongue virus and other orbiviruses.
The end-uses for these products which pose the greatest threat are embryo transfer systems and other uses where the products are introduced directly into animals.
RISK REDUCTION PRIOR TO IMPORTATION
There are two alternative ways of dealing with the risks posed by these products, as follows:
-treatment of the products to inactivate the virus particles -ensuring, as far as possible, that the source of the products is risk-free.
Product treatment
Product treatment may include alteration of the pH, irradiation or heating, but these treatments may affect the structure and hence the properties of the product, rendering it less valuable to the customer.
'Risk-free' sources
Ensuring that sources are risk-free is problematical, particularly where geographical and other factors suggest that there is the possibility of covert infection (e.g. bluetongue). One possible risk-reduction approach is to ensure that the products come from countries or regions which are free from a specific disease. In the case of bluetongue, regional freedom may be sufficient, but for FMD country freedom is desirable.
POST-IMPORTATION RISK REDUCTION
If neither of these pre-importation risk reduction methods is practicable, risk reduction may be achieved post-importation, i.e. by ensuring that the products are so tested or treated that they cannot pose any further risk. Testing products is far from being a fool-proof process, unless there is extensive testing of each and every batch; such testing is rarely a practical proposition.
This leaves post-importation product treatment. In practice, this means 'channelling' the products to commercial and other operations covered by the European medicines legislation, which ensures safety of the final end-product under marketing and authorisation procedures. Such 'channelling' of imported products which are not 'riskfree' contains an element of risk in itself, however, as some products may be diverted without treatment for other uses involving animals. It is therefore essential that the competent veterinary authorities in the importing countries exercise rigid control over the post-importation movements of such material.
It is in this context that EU Member States issue health certificates allowing the importation of 'crude' biological products. At present, the conditions to be satisfied before a certificate is issued vary between Member States, although the basic requirements have been harmonised (1) . The European Commission (DG VI) and the Member States are currently engaged in fully harmonising these conditions to produce a single set of conditions for use throughout the EU. 
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